Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaExtended-spectrum beta-lactamases: a clinical updateExtended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamasesNosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalenceCarbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysisAutomated image analysis for quantification of filamentous bacteriaClinical management of infections caused by multidrug-resistant EnterobacteriaceaeBeyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-LactamasesBacterial temporal dynamics enable optimal design of antibiotic treatmentExtended-spectrum beta-lactamases and clinical outcomes: current data.Increasing prevalence of vancomycin-resistant Enterococcus faecium, expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae, and imipenem-resistant Pseudomonas aeruginosa in Korea: KONSAR study in 2001Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of AmericaExtended Spectrum Beta-lactamase Detection in Gram-negative Bacilli of Nosocomial OriginExtended-spectrum-beta-lactamase, AmpC, and Carbapenemase issuesProteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamasesAcquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infectionsCefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacaeBloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcomeDetermination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study.National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamasesRapid, low-cost fluorescent assay of β-lactamase-derived antibiotic resistance and related antibiotic susceptibility.Modified Double Disc Synergy Test to Detect ESBL Production in Urinary Isolates of Escherichia coli and Klebsiella pneumoniae.Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcomeDiscrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysisAntibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatmentA hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infectionPredictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae.Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella speciesPopulation Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI).Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic testsOccurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases.Extended-spectrum β-lactamase (ESBL) in Omani Children: Study of prevalence, risk factors and clinical outcomes at Sultan Qaboos University Hospital, Sultanate of OmanQuality control for beta-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain.Expert systems in clinical microbiology.ESBLs: A Clear and Present Danger?Extended-spectrum-beta-lactamase producing bacteria related urinary tract infection in renal transplant recipients and effect on allograft functionClinical usefulness of the 2010 clinical and laboratory standards institute revised breakpoints for cephalosporin use in the treatment of bacteremia caused by Escherichia coli or Klebsiella spp.
P2860
Q22241905-B12AA376-FBCB-49D0-9871-4D4B6EF5AB2FQ24534999-117AA973-C5B1-4B1A-AC72-E7DD7E605811Q24650618-D426BDC7-A5CF-4B6B-8C94-8348911095CAQ25257162-2EEA0821-76FF-4AEF-94B9-8C361C81FD43Q27002495-8CA915C9-4D6A-4F8F-9CB5-2ACD92A4F12AQ27316219-58887250-3C9C-4FB5-A2EF-297905663AB7Q28246841-3001BB4C-09C5-4ABB-9D96-A4A0BFAAE05CQ28249617-F8095FBC-E4CE-49A2-931B-A59BEE1A58EFQ28546654-831299FD-BF97-4A65-9211-BC59A54A4A4EQ33236875-3888EC12-DD44-4411-B0EB-4E82BDC443B9Q33654539-C87F3EA5-19DA-428D-9E37-C2234C7E3FEAQ33688646-A9E2609A-35FE-4A51-A63A-0DBEF9012862Q33736461-FDE9E0D7-9400-4DF2-BB78-C22FF63706BCQ33769534-8AD491F1-42E4-42AF-9737-6255C47EE817Q33883791-2233C4E7-08B8-4667-8F08-9B1DE64653BEQ33938132-DDB52C90-EBB3-4A22-A85B-3655B4ED1F3EQ33983667-64FACEF1-9B9C-4F72-B5F9-2A7CF2923B60Q34073514-0CA3A22B-45AC-4FC3-AD73-45E05EDB3A0EQ34106854-83962A24-EEB7-4699-856F-FEB0E654F743Q34139332-93E93996-ED5F-4DB1-A2AB-8996238705B6Q34201311-5FA4DF6F-ADA5-4445-947E-86D5B7F4FFC4Q34269727-B27084CF-3467-4AAC-A689-637B3BFE6F72Q34309458-608D863E-2505-438E-812F-47B46657C123Q34319946-1C00FB3D-F480-4769-AC01-11DF48416F99Q34336140-A7EEDF7D-430F-4B20-A99E-7091AED38DEBQ34351978-4B9AA6C0-C470-4DB7-BEA9-750E6C8D9A59Q34402917-7A105DCF-3CCF-4F9B-8C7C-E0E4E63805C2Q34456773-F1EECA30-76DC-4A01-931C-784F98E0496AQ34582295-F01B066A-56C9-46DA-80CC-343EB0CB8462Q34648809-810D6A28-ACB0-4639-85EF-28FFD2161F20Q34680546-905D7D22-D7A6-4046-9122-54768F5559DEQ34726196-57128667-CEBE-44D6-AE3A-7B502EC8887DQ34749275-75D040BA-CED4-48DE-BC66-1FA7D0F73E26Q34753336-F5AAC61B-7E04-4847-A4A0-8A1FC1ED3CBFQ34783021-7DD0219E-05F4-4898-89F0-3DDACEED691BQ34991064-B4F0F874-0D58-4650-868C-93FEB6AC4120Q35090146-EE8AB183-A987-4542-8E4A-CD6DC663A630Q35101453-27A9A477-8EC7-4B56-A0C7-3ACF76A6545EQ35122946-ABBF19AD-A6D1-4BD8-815C-C55D95931EC1Q35156063-0D57E044-52F7-4745-A10F-714F20D20DA7
P2860
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Outcome of cephalosporin treat ...... nical microbiology laboratory.
@ast
Outcome of cephalosporin treat ...... nical microbiology laboratory.
@en
type
label
Outcome of cephalosporin treat ...... nical microbiology laboratory.
@ast
Outcome of cephalosporin treat ...... nical microbiology laboratory.
@en
prefLabel
Outcome of cephalosporin treat ...... nical microbiology laboratory.
@ast
Outcome of cephalosporin treat ...... nical microbiology laboratory.
@en
P2093
P2860
P1476
Outcome of cephalosporin treat ...... inical microbiology laboratory
@en
P2093
A Von Gottberg
J G McCormack
J M Casellas
K P Klugman
L Mulazimoglu
R A Bonomo
P2860
P304
P356
10.1128/JCM.39.6.2206-2212.2001
P407
P577
2001-06-01T00:00:00Z